Jennison Health Sciences Fund Reopens

JennisonDryden reopened the Jennison Health Sciences Fund (Class A: PHLAX) to all investors, effective immediately.

According to a press release, the fund has been a Lipper Fund Award winner for the last four years—most recently with the Jennison Health Sciences Fund (Class Z shares) winning the Lipper Award for five-year performance out of 90 funds in the health/biotechnology category for the period ending December 31.

“Reopening the fund gives the investment team the ability to take advantage of current market conditions,” said Scott Benjamin, senior vice president and head of product and marketing for JennisonDryden, in the release. “A confluence of medical, regulatory, legal, and market trends offers unprecedented opportunity for the fund’s seasoned healthcare team to make investment choices that give investors the potential for financial growth, particularly over the long-term.”

David Chan, Jennison’s health sciences equity portfolio manager and analyst, and Michael Del Balso, Jennison’s director of research for growth equity and a large-cap growth equity portfolio manager, manage the fund.

JennisonDryden is the proprietary mutual fund family of Prudential Financial, Inc.

More information is available at